Diagnostyka

In April 2011, MidEuropa acquired a strategic stake in Diagnostyka, the largest medical laboratory chain in Poland offering comprehensive diagnostic laboratory services to hospitals, corporate, and individual customers. Shortly after the investment, MidEuropa supported the transformational acquisition of Teresa Fryda Laboratorium Medyczne (Fryda) in December 2011. Since then, the company has completed many follow-on acquisitions, which, combined with strong and consistent organic growth, have created an undisputed market leader.

Drawing on its deep experience in the healthcare sector years prior to the investment, MidEuropa recognised the attractive consolidation opportunity for laboratory services in Poland. Diagnostyka operates in a very promising, long-term growth sub-sector within healthcare services, fuelled by significant under-penetration and the relatively low long-term cost of providing services which have high positive impact on healthcare outcomes, by emphasising early detection and preventive treatments.

Thanks to a well-executed buy-and-build consolidation strategy, coupled with investments in large-scale and technologically advanced laboratory infrastructure and digitalisation, Diagnostyka has gradually transformed from a regional, founder-led business into a national champion. Its scale and comprehensive scope of service ensure the company plays a critical role in offering good and expanding access to diagnostic services to the over 20 million patients it serves annually.

Diagnostyka debuted on the Warsaw Stock Exchange on Friday, February 7, 2025. The market closing price on the first day of trading put Diagnostyka’s market capitalisation at over €1 billion, ranking the company as the second-largest publicly listed healthcare services provider in Central Europe and among the top seven largest listed sector players in Europe at the time of listing.

Partnership highlights:

• M&A strategy: Since MidEuropa’s investment, Diagnostyka has completed 128 follow-on acquisitions, which, combined with strong and consistent organic growth, have created an undisputed market leader, with a size surpassing the two largest competitors combined
• In 2021, the company launched a new state-of-the-art facility in Warsaw and, at over 10,000sqm and with the ability to process up to 250,000 tests daily, it is one of the largest and most modern clinical laboratories in Europe
• Digital transformation: Diagnostyka continues to follow a comprehensive plan to improve its digital capabilities. The company invests into the new Laboratory Information Management System, BI software, new CRM, as well as various tools for increased patient engagement
• Expansion into adjacent categories: Diagnostyka conducted its first imagining diagnostics acquisition in 2023 with planned further expansion in this adjacent vertical

 Value creation: 

• Growth Acceleration
• Operational Excellence
• Digitalisation